Aarti Pharmalabs Share Price
Aarti Pharmalabs Share Price Today
As of 5 Jul 2026, Aarti Pharmalabs share price is ₹706.35. The stock opened at ₹699.85, compared to its previous close of ₹697.20. During today's trading session, Aarti Pharmalabs share price moved in the range of ₹698.55 to ₹718.95, with an average price of ₹708.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹585.00 and a high of ₹971.00. On the performance front, Aarti Pharmalabs share price has declined by 4.82% over the last six months and is down 21.90% on a year-on-year basis.
Aarti Pharmalabs Returns Calculator
Aarti Pharmalabs Shareholder Returns
Aarti Pharmalabs Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Aarti Pharmalabs Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹2,115.07 | ₹1,852.61 | ₹1,945.23 | ₹1,199.94 |
| Other Income | ₹10.12 | ₹4.90 | ₹2.38 | ₹2.51 |
| Total Revenue | ₹2,125.19 | ₹1,857.50 | ₹1,947.61 | ₹1,202.46 |
| Total Expenses | ₹1,764.50 | ₹1,557.01 | ₹1,686.83 | ₹1,047.08 |
| Profit Before Tax | ₹360.69 | ₹300.49 | ₹260.77 | ₹155.38 |
| Tax | ₹88.28 | ₹83.59 | ₹67.28 | ₹33.13 |
| Profit After Tax | ₹272.40 | ₹216.90 | ₹193.49 | ₹122.25 |
| EPS - Basic | ₹30.06 | ₹23.93 | ₹21.35 | ₹13.49 |
| EPS - Diluted | ₹30.04 | ₹23.93 | ₹21.35 | ₹13.49 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹360.69 | ₹300.49 | ₹260.77 | ₹155.38 |
| Income before WC changes | ₹482.15 | ₹395.14 | ₹342.60 | ₹207.79 |
| Change in Assets | -₹29.15 | -₹165.20 | -₹147.42 | -₹158.50 |
| Change in Liabilities | -₹56.91 | ₹43.35 | ₹130.20 | -₹71.86 |
| Change in WC | -₹86.07 | -₹121.85 | -₹17.22 | -₹230.36 |
| Cash flow from Operations | ₹331.56 | ₹216.35 | ₹263.00 | -₹43.70 |
| Cash flow from Investing | -₹413.90 | -₹214.56 | -₹157.80 | -₹138.74 |
| Cash flow from Financing | ₹65.44 | ₹9.72 | -₹163.47 | ₹260.38 |
| Total Cash Flow | -₹16.90 | ₹11.51 | -₹58.28 | ₹77.94 |
| Cash (Start of the year) | ₹23.63 | ₹12.12 | ₹83.27 | ₹5.33 |
| Cash (End of the year) | ₹6.73 | ₹23.63 | ₹25.00 | ₹83.27 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,584.24 | ₹1,236.46 | ₹1,075.17 | ₹1,011.75 |
| Current Assets | ₹1,322.17 | ₹1,345.64 | ₹1,155.76 | ₹1,028.15 |
| Total Assets | ₹2,906.41 | ₹2,582.11 | ₹2,230.93 | ₹2,039.90 |
| Current Liabilities | ₹657.05 | ₹694.39 | ₹591.57 | ₹580.66 |
| Net Current Asset | ₹665.12 | ₹651.25 | ₹564.19 | ₹447.48 |
| Non-Current Liabilities | ₹259.45 | ₹130.68 | ₹80.87 | ₹72.76 |
| Equity Capital | ₹1,989.91 | ₹1,757.04 | ₹1,558.49 | ₹1,386.48 |
| Total Equity & Liabilities | ₹2,906.41 | ₹2,582.11 | ₹2,230.93 | ₹2,039.90 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,771.35 | ₹1,502.13 | ₹1,511.25 | ₹941.02 |
| Other Income | ₹14.49 | ₹11.01 | ₹1.28 | ₹2.51 |
| Total Revenue | ₹1,785.84 | ₹1,513.14 | ₹1,512.53 | ₹943.53 |
| Total Expenses | ₹1,449.50 | ₹1,238.62 | ₹1,279.17 | ₹809.81 |
| Profit Before Tax | ₹336.34 | ₹274.52 | ₹233.36 | ₹133.73 |
| Tax | ₹78.99 | ₹73.87 | ₹61.63 | ₹27.00 |
| Profit After Tax | ₹257.35 | ₹200.65 | ₹171.73 | ₹106.73 |
| EPS - Basic | ₹28.39 | ₹22.14 | ₹18.95 | ₹11.78 |
| EPS - Diluted | ₹28.38 | ₹22.14 | ₹18.95 | ₹11.78 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹336.34 | ₹274.52 | ₹233.36 | ₹133.73 |
| Income before WC changes | ₹445.39 | ₹355.23 | ₹310.23 | ₹179.81 |
| Change in Assets | -₹89.88 | -₹168.87 | -₹129.45 | -₹193.85 |
| Change in Liabilities | ₹42.99 | ₹44.32 | ₹91.84 | -₹35.80 |
| Change in WC | -₹46.88 | -₹124.55 | -₹37.61 | -₹229.65 |
| Cash flow from Operations | ₹340.01 | ₹183.69 | ₹215.88 | -₹64.84 |
| Cash flow from Investing | -₹419.80 | -₹184.40 | -₹115.55 | -₹133.54 |
| Cash flow from Financing | ₹78.63 | ₹4.40 | -₹156.53 | ₹254.63 |
| Total Cash Flow | -₹1.16 | ₹3.70 | -₹56.20 | ₹56.25 |
| Cash (Start of the year) | ₹4.00 | ₹0.30 | ₹56.50 | ₹0.25 |
| Cash (End of the year) | ₹2.84 | ₹4.00 | ₹0.30 | ₹56.50 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,510.81 | ₹1,162.85 | ₹1,010.15 | ₹936.56 |
| Current Assets | ₹1,212.80 | ₹1,134.06 | ₹966.22 | ₹890.27 |
| Total Assets | ₹2,723.61 | ₹2,296.91 | ₹1,976.37 | ₹1,826.83 |
| Current Liabilities | ₹622.33 | ₹555.58 | ₹463.75 | ₹481.67 |
| Net Current Asset | ₹590.47 | ₹578.48 | ₹502.47 | ₹408.60 |
| Non-Current Liabilities | ₹257.40 | ₹119.87 | ₹74.04 | ₹60.88 |
| Equity Capital | ₹1,843.87 | ₹1,621.46 | ₹1,438.58 | ₹1,284.28 |
| Total Equity & Liabilities | ₹2,723.61 | ₹2,296.91 | ₹1,976.37 | ₹1,826.83 |
About Aarti Pharmalabs
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives, based in India. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Aarti Pharmalabs Financial Highlights
- Revenue: Aarti Pharmalabs reported revenue of ₹1,829.19 crore in FY26 vs ₹2,125.19 crore in FY25. It showed a decrease of 13.93% on a yearly basis.
- Operating Profit: Aarti Pharmalabs reported an operating profit of ₹232.92 crore in FY26 vs ₹360.69 crore in FY25. It showed a decrease of 35.42% on a year-on-year basis.
- Net Profit: Aarti Pharmalabs reported a net profit of ₹174.71 crore in FY26 vs ₹272.40 crore in FY25. It showed a decrease of 35.86% on a yearly basis.
Aarti Pharmalabs Quarterly Result Highlights
- Aarti Pharmalabs reported revenue of ₹590.69 crore in Mar 2026, compared with ₹431.90 crore in Dec 2025, representing an increase of 36.77% on a quarter-on-quarter (QoQ) basis.
- Aarti Pharmalabs reported an operating profit of ₹81.68 crore in Mar 2026, compared with ₹62.87 crore in Dec 2025, representing an increase of 29.92% on a quarter-on-quarter (QoQ) basis.
- Aarti Pharmalabs reported a profit of ₹61.12 crore in Mar 2026, compared with ₹47.96 crore in Dec 2025, reflecting an increase of 27.44% on a QoQ basis.
- The earnings per share (EPS) of Aarti Pharmalabs stood at ₹30.06 during Mar 2026.
Similar Stocks
FAQs on Aarti Pharmalabs Share Price
What is Aarti Pharmalabs share price today?
Aarti Pharmalabs share price is ₹706.35 as on 03 Jul, 2026, 15:57 IST.
How has the Aarti Pharmalabs share price performed in the past?
In the last 1 year, Aarti Pharmalabs delivered a return of -21.90%. The Aarti Pharmalabs share price hit a high of ₹971.00 and low of ₹585.00.
How much is the Mutual Fund shareholding in Aarti Pharmalabs shares?
The Mutual Fund Shareholding in Aarti Pharmalabs was 0.80% at the end of Mar 2026.
What is the the 52-week high and low of Aarti Pharmalabs shares ?
The 52-week high and low of Aarti Pharmalabs share is ₹971.00 and ₹585.00 as of 03 Jul, 2026.
What is the market cap of Aarti Pharmalabs?
The market capitalisation of Aarti Pharmalabs is ₹6,334.71 Crores as on 03 Jul, 2026.
What are the stock symbols of Aarti Pharmalabs?
The stock symbol of Aarti Pharmalabs is AARTIPHARM on the NSE, 543748 on the BSE, and the ISIN is INE0LRU01027.
What was yesterday's closing price of Aarti Pharmalabs shares ?
Aarti Pharmalabs shares closed yesterday at ₹697.20 on NSE & ₹698.75 on BSE
How to buy Aarti Pharmalabs shares?
To buy Aarti Pharmalabs shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Aarti Pharmalabs shares on Holidays?
No, shares of Aarti Pharmalabs or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Aarti Pharmalabs shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Aarti Pharmalabs?
The PE and PB ratio of Aarti Pharmalabs is 36.26 and 2.98 respectively, as on 03 Jul, 2026, 15:57 IST.
